US 11,723,545 B2
Ambulatory dehydration monitoring during cancer therapy
Pramodsingh Hirasingh Thakur, Woodbury, MN (US); Jeffrey E. Stahmann, Ramsey, MN (US); Viktoria A. Averina, Shoreview, MN (US); Deepa Mahajan, North Oaks, MN (US); and Bruce R. Forsyth, Hanover, MN (US)
Assigned to Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed by Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed on Dec. 8, 2020, as Appl. No. 17/115,503.
Claims priority of provisional application 62/956,460, filed on Jan. 2, 2020.
Prior Publication US 2021/0204874 A1, Jul. 8, 2021
Int. Cl. A61B 5/0205 (2006.01); A61B 5/00 (2006.01); A61B 5/0537 (2021.01); A61B 5/11 (2006.01); A61B 7/00 (2006.01); A61B 5/08 (2006.01); A61B 5/024 (2006.01)
CPC A61B 5/0205 (2013.01) [A61B 5/0537 (2013.01); A61B 5/1116 (2013.01); A61B 5/1118 (2013.01); A61B 5/4875 (2013.01); A61B 5/7282 (2013.01); A61B 7/00 (2013.01); A61B 5/024 (2013.01); A61B 5/0816 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A system for determining patient dehydration during cancer therapy, comprising:
a signal receiver circuit configured to receive first and second physiologic information of a patient, the first physiologic information comprising heart sound information of the patient, and the second physiologic information comprising information different than the first physiologic information; and
an assessment circuit, coupled to a therapy circuit, the assessment circuit configured to:
determine an indication of patient dehydration associated with cancer therapy using the received first and second physiologic information; and
provide cancer therapy adjustment information at an output based on the determined indication of patient dehydration.